*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those
*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with
Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto
The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR
We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with
*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events)
*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and
*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of
*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the
